BMO Capital Reaffirms Their Buy Rating on SAGE Therapeutics

By Carrie Williams

In a report issued on July 26, Gary Nachman from BMO Capital reiterated a Buy rating on SAGE Therapeutics (NASDAQ: SAGE), with a price target of $82. The company’s shares closed yesterday at $81.82, close to its 52-week high of $88.93.

According to TipRanks.com, Nachman is a 5-star analyst with an average return of 15.3% and a 65.8% success rate. Nachman covers the Healthcare sector, focusing on stocks such as Amphastar Pharmaceuticals, Sucampo Pharmaceuticals, and Pacira Pharmaceuticals.

Currently, the analyst consensus on SAGE Therapeutics is Strong Buy and the average price target is $91.78, representing a 12.2% upside.

In a report issued on July 11, Stifel Nicolaus also reiterated a Buy rating on the stock with a $90 price target.

The company has a one year high of $88.93 and a one year low of $35.02. Currently, SAGE Therapeutics has an average volume of 370.2K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

SAGE Therapeutics, Inc. is a clinical stage biopharmaceutical company. The company engages in the development and commercialization of novel medicines to treat central nervous system disorders.